Hospira Inc.

• E-mail

E-mail this article
To:
Invalid E-mail address
Add a personal message:(80 character limit) Your E-mail:
Invalid E-mail address

Sending your article
Your article has been sent.

The maker of anesthesia and cancer treatments is being scrutinized by regulators over flaws in its manufacturing practices. It may face widespread production breakdowns that could take two to three years to correct, RBC Capital Markets analyst Shibani Malhotra said. Hospira has been working to correct flaws that led to recalls of two drugs in 2009 and 2010. It could be vulnerable to takeover, Malhotra said.

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Sign up

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

Start here

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.

• E-mail

E-mail this article
To:
Invalid E-mail address
Add a personal message:(80 character limit) Your E-mail:
Invalid E-mail address

Sending your article
Your article has been sent.